[{"address1": "5858 Horton Street", "address2": "Suite 455", "city": "EmeryVille", "state": "CA", "zip": "94608", "country": "United States", "phone": "510 505 2680", "website": "https://www.4dmoleculartherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.", "fullTimeEmployees": 227, "companyOfficers": [{"maxAge": 1, "name": "Dr. John F. Milligan Ph.D.", "age": 63, "title": "Executive Chairman", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 150000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David H. Kirn M.D.", "age": 62, "title": "Co-Founder, CEO & Director", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 1009003, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Fariborz  Kamal Ph.D.", "age": 61, "title": "President & COO", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 734607, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Theresa  Janke", "age": 49, "title": "Co-Founder & Chief of Staff", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 652315, "exercisedValue": 0, "unexercisedValue": 703125}, {"maxAge": 1, "name": "Mr. Kristian  Humer M.B.A.", "age": 49, "title": "CFO & Principal Financial Officer", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ashoo  Gupta", "age": 48, "title": "Principal Accounting Officer & Principal Financial Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott P. Bizily J.D., Ph.D.", "age": 52, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. An  Song Ph.D.", "title": "Chief Translational Medicine Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Noriyuki  Kasahara M.D., Ph.D.", "age": 61, "title": "Chief Scientific Advisor & Member of Scientific Advisory Board", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 201288, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.", "age": 63, "title": "Senior VP & Therapeutic Area Head of Pulmonology", "yearBorn": 1961, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1761955200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 10.99, "open": 11.11, "dayLow": 10.8675, "dayHigh": 11.89, "regularMarketPreviousClose": 10.99, "regularMarketOpen": 11.11, "regularMarketDayLow": 10.8675, "regularMarketDayHigh": 11.89, "payoutRatio": 0.0, "beta": 2.951, "forwardPE": -3.5440729, "volume": 660993, "regularMarketVolume": 660993, "averageVolume": 816319, "averageVolume10days": 731820, "averageDailyVolume10Day": 731820, "bid": 11.63, "ask": 11.74, "bidSize": 3, "askSize": 3, "marketCap": 666195008, "fiftyTwoWeekLow": 2.235, "fiftyTwoWeekHigh": 12.34, "allTimeHigh": 55.11, "allTimeLow": 2.235, "priceToSalesTrailing12Months": 5551.625, "fiftyDayAverage": 9.933, "twoHundredDayAverage": 5.82115, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 383394976, "profitMargins": 0.0, "floatShares": 42919868, "sharesOutstanding": 57135075, "sharesShort": 5188480, "sharesShortPriorMonth": 4219162, "sharesShortPreviousMonthDate": 1760486400, "dateShortInterest": 1763078400, "sharesPercentSharesOut": 0.0908, "heldPercentInsiders": 0.03226, "heldPercentInstitutions": 0.71998, "shortRatio": 5.28, "shortPercentOfFloat": 0.0938, "impliedSharesOutstanding": 57135075, "bookValue": 7.889, "priceToBook": 1.4780073, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -209176992, "trailingEps": -3.75, "forwardEps": -3.29, "enterpriseToRevenue": 3194.958, "enterpriseToEbitda": -1.722, "52WeekChange": 0.44795787, "SandP52WeekChange": 0.1265819, "quoteType": "EQUITY", "currentPrice": 11.66, "targetHighPrice": 45.0, "targetLowPrice": 17.0, "targetMeanPrice": 33.11111, "targetMedianPrice": 33.0, "recommendationMean": 1.54545, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 305063008, "totalCashPerShare": 5.339, "ebitda": -222704992, "totalDebt": 22263000, "quickRatio": 8.221, "currentRatio": 8.418, "totalRevenue": 120000, "debtToEquity": 6.034, "revenuePerShare": 0.002, "returnOnAssets": -0.27636, "returnOnEquity": -0.45378, "grossProfits": -177955008, "freeCashflow": -103545376, "operatingCashflow": -183496000, "revenueGrowth": 29.0, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -655.3889, "financialCurrency": "USD", "symbol": "FDMT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1764364947, "regularMarketTime": 1764363600, "exchange": "NMS", "messageBoardId": "finmb_272879653", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "earningsTimestampStart": 1762781400, "earningsTimestampEnd": 1762781400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -3.75, "epsForward": -3.29, "epsCurrentYear": -3.2586, "priceEpsCurrentYear": -3.5782237, "fiftyDayAverageChange": 1.7270002, "fiftyDayAverageChangePercent": 0.17386493, "twoHundredDayAverageChange": 5.83885, "twoHundredDayAverageChangePercent": 1.0030407, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-12-11", "averageAnalystRating": "1.5 - Buy", "cryptoTradeable": false, "regularMarketChangePercent": 6.096452, "regularMarketPrice": 11.66, "shortName": "4D Molecular Therapeutics, Inc.", "longName": "4D Molecular Therapeutics, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1607697000000, "postMarketChangePercent": -2.744423, "postMarketPrice": 11.34, "postMarketChange": -0.3199997, "regularMarketChange": 0.6700001, "regularMarketDayRange": "10.8675 - 11.89", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 816319, "fiftyTwoWeekLowChange": 9.425, "fiftyTwoWeekLowChangePercent": 4.2170024, "fiftyTwoWeekRange": "2.235 - 12.34", "fiftyTwoWeekHighChange": -0.6800003, "fiftyTwoWeekHighChangePercent": -0.055105373, "fiftyTwoWeekChangePercent": 44.795788, "earningsTimestamp": 1762781400, "marketState": "CLOSED", "displayName": "4D Molecular Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-29"}]